Show simple item record

dc.contributor.authorGarg, Mamta
dc.date.accessioned2022-03-15T16:30:24Z
dc.date.available2022-03-15T16:30:24Z
dc.date.issued2022-03-01
dc.identifier.citationDelimpasi, S., Mateos, M. V., Auner, H. W., Gavriatopoulou, M., Dimopoulos, M. A., Quach, H., Pylypenko, H., Hájek, R., Leleu, X., Dolai, T. K., Sinha, D. K., Venner, C. P., Benjamin, R., Garg, M. K., Doronin, V., Levy, Y., Moreau, P., Chai, Y., Arazy, M., Shah, J., … Grosicki, S. (2022). Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American journal of hematology, 97(3), E83–E86. https://doi.org/10.1002/ajh.26434en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15269
dc.description.abstractNo abstract available.
dc.description.urihttps://onlinelibrary.wiley.com/doi/10.1002/ajh.26434en_US
dc.subjectmultiple myelomaen_US
dc.subjectrenal impairmenten_US
dc.subjectselinexoren_US
dc.subjectbortezomiben_US
dc.subjectdexamethasoneen_US
dc.titleEfficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON studyen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttps://doi.org/10.1002/ajh.26434en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2021-12-29
html.description.abstractNo abstract available.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record